NPR2 and Severe short stature: This crosstalk between natriuretic peptide receptor 2 and MAPK alleviates the disruption to endochondral bone growth.7 In achondroplasia mouse models, vosoritide treatment significantly improves bone growth, corrects growth-plate defects, and reduces dwarfism-related skeletal morphologies, including notable changes to the skull.9